Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients

  • Lee, Seung-Jun; 
  • Lee, Yong-Joon; 
  • Lee, Kyounghoon; 
  • Cho, Deok-Kyu; 
  • Cho, Yun-Hyeong; 
  • ... Park, Yong Hwan; 
  • 외 23명
Citations

WEB OF SCIENCE

0

초록

Background The effect of clopidogrel monotherapy as compared with extended dual antiplatelet therapy (DAPT) with clopidogrel and aspirin beyond 12 months after implantation of a drug-eluting stent remains uncertain in patients at high risk for recurrent ischemic events. Methods In this open-label noninferiority trial conducted in South Korea, we enrolled patients with high-risk clinical or lesion characteristics in whom a drug-eluting stent had been implanted 12 months earlier and randomly assigned them, in a 1:1 ratio, to receive clopidogrel monotherapy or extended DAPT (clopidogrel plus aspirin). The primary end point was net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding at 24 months (noninferiority margin, 2.3 percentage points). Key secondary ischemic and bleeding end points were tested in a prespecified hierarchical order. Results Of the 3203 patients who underwent randomization, 1601 were assigned to receive clopidogrel monotherapy and 1602 to receive extended DAPT. Over the course of 24 months, a primary end-point event occurred in 80 patients (5.0%) in the monotherapy group and in 81 (5.1%) in the DAPT group (risk difference, -0.1 percentage points; 90% confidence interval [CI], -1.3 to 1.2; P=0.001 for noninferiority). Death from any cause, myocardial infarction, stent thrombosis, or stroke (the key secondary ischemic end point) occurred in 60 patients (3.7%) in the monotherapy group and in 26 (1.6%) in the DAPT group (hazard ratio, 2.33; 95% CI, 1.47 to 3.69; P<0.001). BARC type 2, 3, or 5 bleeding (the key secondary bleeding end point) occurred in 28 patients (1.8%) in the monotherapy group and in 65 (4.1%) in the DAPT group (hazard ratio, 0.43; 95% CI, 0.27 to 0.67; P<0.001). The incidence of serious adverse events was similar in the two groups. Conclusions Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months. (Funded by Chong Kun Dang and Samjin; A-CLOSE ClinicalTrials.gov number, NCT03947229.)

키워드

STENT IMPLANTATION; OPEN-LABEL; MONOTHERAPY; ASPIRIN; DEFINITIONS; VALIDATION; EFFICACY; TRIALS; SAFETY
제목
Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients
저자
Lee, Seung-Jun; Lee, Yong-Joon; Lee, Kyounghoon; Cho, Deok-Kyu; Cho, Yun-Hyeong; Ahn, Sung Gyun; Yun, Kyeong Ho; Jang, Ji-Yong; Kim, Seunghwan; Kim, Yong Hoon; Park, Yong Hwan; Kwon, Sung Uk; Hur, Seung-Ho; Kang, Tae Soo; Shin, Eun-Seok; Lee, Jin Bae; Jeon, Ki-Hyun; Kim, Ung; Kim, Won Ho; Hong, Bum-Kee; Lee, Sang-Hyup; Hong, Sung-Jin; Ahn, Chul-Min; Kim, Jung-Sun; Ko, Young-Guk; Choi, Donghoon; Hong, Myeong-Ki; Jang, Yangsoo; Kim, Byeong-Keuk
DOI
10.1056/NEJMoa2608533
발행일
2026-08-29
유형
Article; Early Access
저널명
New England Journal of Medicine